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Marcian E. Van Dort, David L. Gildersleeve and Donald M. Wieland 
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Summary 
The synthesis of two tritium labeled sympathomimetic amines, (R)-(-)-phenylephrine and 
(1 R,2S)- ( - ) -whydroxyephedrine,  is described. The tritium label was introduced into the 
aromatic ring in the final step by catalytic reductive dehalogenation of the corresponding iodinated 
precursor. (1 R,2S)-(-)-mmhydroxyephedrine was synthesized in four steps from 
commercially available metaraminol. A novel HPLC purification method provided the labeled 
compounds in a medium ready for direct animal evaluation. Chemical and radiochemical purity was 
>98%; specific activity was 5 22 Cilmmol. 
Keywords: aekhydroxyephedrine, phenylephrine, tritium-labeled sympathomimetic amines, 
heart neuronal markers, adrenergic nerves. 
Our laboratory has actively pursued the synthesis of radiolabeled sympathomimetic amines 
for use in neuronal imaging of the heart. We recently reported the marked accumulation of 6-[F 
18]fluorometaraminol in the adrenergic neurons of the heart. (1) This agent has successfully 
undergone preclinical evaluation as a myocardial imaging agent but its low specific activity 
precluded clinical studies (2). This development has prompted us to investigate the neuronai 
specificity of the structurally related sympathomimetic amines phenylephrine and W- 
hydroxyephedrine. Both of these amines bear an N-methyl group and are thus amenable to labeling 
in high specific activity with [C-1 llmethyl iodide for positron emission tomography studies. Our 
initial strategy, therefore, was to tritium label these amines for evaluation in inw biological 
screening tests that would hopefully identify the optimum agent for subsequent C-labeling. 
Since previous reports have demonstrated the importance of the R(-)configuration at the 
benzylic position for intraneuronal granular storage (3,4), we focused our attention on the 1R and 
1 R,2S isomers of phenylephrine and &-hydroxyephedrine, respectively. Literature evidence 
suggests that biogenic amines labeled with tritium at position 8 of the side chain (ie. on the alpha 
'This work was presented in part at the July, 1989. Society of Nuclear Medicine Meeting; Abstract 
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carbon) are susceptible to metabolic loss of label (5). Our objective was therefore to achieve a 
regiospecific incorporation of tritium into phenylephrine and Lnefa-hydroxyephedrine in a final 
synthetic step by catalytic reductive dehalogenation of the appropriate aromatic ring-iodinated 
precursors. In this report we detail the synthesis of these two aromatic ring 3H- labeled 
sympathomimetic amines and their iodinated precursors. 
P 
Since (1 R,2S)-(-)---hydroxyephedrine (4) was not available from commercial 
sources and its synthesis was not reported in the literature, we chose to synthesize it  from 
commercially avai lable (1R,2S) - ( - ) -3 -hydroxy-~- [ l - (aminoethy l ) ]benzenemethano l  
(metaraminol). Our initial attempts to synthesize 4 by direct reductive N-methylation of 
metaraminol with HCHOINaH2P03 by the procedure of Loibner et al (6) afforded a product 
identified by NMR as a 1,2.3,4 tetrahydroisoquinoline analog. There is literature precedence for a 
similar pathway in the reaction of phenylephrine with aldehydes (7). A multistep approach was 
therefore devised to prepare 4 as shown in Scheme I. Utilizing a procedure adapted from Boger and 
coworkers (8), metaraminol bitartrate was treated with benzylchloroformate and sodium carbonate 
to afford the carbamate 1 in 90% yield. The use of the carbamate functionality which served later 
as the precursor to the N-methyl group, also aliowed easy purification of the intermediates by 
normal phase column chromatography. Protection of the phenol as its benzyl ether 2 was 
accomplished by treatment of 1 with benzylbromide and potassium carbonate in dry DMF. 
Subsequent reduction of 2 with lithium aluminum hydride provided 3 in good yield (86Yo). The 
benzyl protecting group was removed by catalytic hydrogenolysis of 3 with 5% Pd-C to afford a- 
hydroxyephedrine 4 in 95% yield. The physical properties of 4 (i.e. mp, H and 3C NMR, and 
optical rotation) matched those of a small analytical sample generously provided by Sterling 
Winthrop Research Insititute. Rensselaer, New York. lodinations of w -hyd roxyephedr ine  and 
phenylephrine were performed in 10 M aqueous NH40H with equimolar amounts of ethanolic 12 
using a procedure adapted from Michel and coworkers (9) to give the corresponding 4iodinated 
analogs (Scheme 1 1 ) .  This is consistent with our previous findings in the iodination of metaraminol 
(2) and m - o c t o p a m i n e  by this method which in the latter case afforded the known 4-iodo analog 
( 1 0 ) .  
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[3H]-4 and I3H l -g  were prepared by catalytic reductive deiodination of 5 and L 
respectively, in the presence of tritium gas using a 1:l mixture of 10% Pd-C and 10% Pd-CaCOg 
(Scheme Ill). Although the regiospecificity of tritium incorporation in the 4 position was not 
confirmed by tritium NMR, reductive tritiodehalogenation of similar biogenic amines such as 
R T,;1 O%Pd/Carbon:CaCO, 
0.2M Sodium phosphate 
buffer (pH=7.0) 
R H; PHENYLEPHRINE 
R = CH3; m-HYDROXYEPHEDRINE 
octopamine is known to give regiospecific incorporation (1 1 ). Confirmation that racemization at 
the P-hydroxy carbon did not take place during the tritiation procedure is based on the following 
evidence: a) hydrogenation of 9 and 1 conducted under identical conditions used for the tritiation 
procedure afforded 4 and 6, respectively, with optical rotation values and spectroscopic properties 
that matched those of authentic samples; b) HPLC comparison of 11 with a diastereomeric mixture 
obtained by partially racemizing 4 in refluxing 6N HCI (12). Radiochemical purity of [3H]-& and 
[3H]-6 was 88% and 99%, respectively, as assessed by radio-TLC. Further purification, which 
afforded 98% radiochemical and chemical purity, was carried out by preparative reverse phase 
HPLC in which the labeled compounds were completely separated from their iodinated precursors. 
An attractive aspect of this purification method was the use of 0.2 M H0Ac:EtOH (9:l) as the HPLC 
eluant which eliminated the need for solvent evaporation prior to formulation for animal studies. A 
simple dilution of the labeled compound to the required specific concentration of radioactivity with 
0.1 5 M sodium acetate buffer (pH=4.5) was sufficient for i.v. administration to rats. 
EXPERlMENTAL 
Metaraminol bitartrate was obtained from Sigma Chemical Company, St. Louis, MO. The 10% 
Pd/CaCOg was purchased from BHD Chemicals Ltd, Poole, England. An analytical sample of 
(1 R,2Sf-(-)---hydroxyephedrine as the hydrochloride salt was obtained as a gift from 
Sterling-Winthrop Research Institute, Rensselaer, N.Y. R-(-)-PhenylephrineHCI and all other 
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chemical reagents were obtained from Aldrich Chemical Company, Milwaukee, WI. Flash 
chromatography was performed by the method of Still (13). Melting points were determined 
on a Fisher-Johns melting point apparatus and are uncorrected. Infrared spectra were recorded on a 
Perkin-Elmer 7278 spectrometer. H-NMR spectra were obtained on a Bruker WM-360 (360 
MHz) instrument. ISC-NMR spectra were recorded on a Bruker WM-360 instrument at 90.5 MHz 
and are completely decoupled. Mass spectra were obtained on a Finnigan 4021 GCMSlDS (low 
resolution) or a UG70-2503 (high resolution) instrument. Optical rotations were recorded on a 
Perkin-Elmer EM-241 polarimeter. Elemental analyses were performed by Spang Microanalytical 
Laboratories, Eagle Harbor, MI. 
Thin layer chromatography of the radioactive products (Radio-TLC) were performed on 
either Whatman K6F silica gel glass-backed plates (20 cm, 2501) or Whatman KC1*F reversed 
phase glass-backed plates (20 cm, 200~) .  Radio-TLC chromatograms were scanned on a Berthold 
Model LB 2832 TLC-linear analyzer equipped with a Model LB 500 data acquisition system. 
HPLC was carried out on either a Waters system consisting of a Model 680 automated 
gradient controller, two Model 510 pumps, a Model U6K injection and Kratos Model SF773 UV 
detector or Beckman Instrument Model 344 gradient liquid chromatograph equipped with a Beckman 
Model 155-00 UV detector. Radioactivity was monitored with a Radiomatic Instruments Model 
DRllC Flo-One radioactive flow detector with a Model CU data acquisition system upgrade containing 
a 340 pL solid scintillant cell. UV absorbance was monitored in all cases at 280 nm. 
Specific activity determinations were estimated from a standard curve relating mass to UV 
absorbance peak area as described previously (14). 
I 1  R . 2 S ~ - 3 - H v d r o x v - a - l l - ~ b e n z v l o x v c a r b o n v l a m i n o ~ e t h v l l  benzenemethanol (1 ). 
Metaraminol bitartrate (10.0 g, 31.5 mmol) in a two-phase mixture of H20:Et20 (200 
mL:160 mL) was treated successively with sodium carbonate (10.0 g, 94.5 mmol) and benzyl 
chloroformate (5.38 g. 31.5 mmol) and stirred at room temperature for 18 h. The ether layer was 
removed, the aqueous layer extracted further with EtpO (2 x 100 mL) and the combined organic 
layers washed with saturated brine (200 mL) and dried (Na2S04). Removal of the solvent i n m  
and recrystalization of the crude product from Et0Ac:hexanes (1:4) gave 8.6 g (90%) of 
analytically pure material: mp 11 9-120°C; IR (KBr) 3420, 3260, 1680, 1665 cm- l  ; H NMR 
(CDC13) 6 7.37-7.33 (m, 5, Ar-H), 7.19 (t, 1, Ar-H), 6.87-6.74 (m, 3. Ar-H) 5.11 (s, 2, 0- 
CHpAr), 4.99 (d, 1, J=9.08 Hz, CHOH), 4.83 (s, 1, NH), 4.07-4.01 (m,l, CHCHg), 1.63 (s, 1, 
OH), 0.99 (d, 3, J=6.91 Hz, C b ) .  
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Anal. Calcd. for C17HigN04: C, 67.76; H, 6.35; N, 4.65. Found: C, 67.78; 
H, 6.37; N, 4.56. 
11 R . 2 S )  _ _  3 Ben- _ _  a I1 - (benzvloxvcarbonvlamino~ethvl lbenzenemethUld 
U 
A mixture of l ( 8 . 2 0  g. 27.2 mmol) and anhydrous K2CO3 (7.52 g, 54.4 mmol) in dry DMF 
(45 mL) was treated with benzyl bromide (4.65 g, 27.2 mmol) and tetrabutylammonium iodide 
(1.0 g, 2.7 mmol) and stirred under an argon atmosphere at ambient temperature for 6 h. The 
reaction mixture was filtered and the residue washed with dry DMF (5 mL). The combined filtrates 
were treated with H 2 0  (50 mL) and extracted with EtOAc (3x100 ml). The organic extract was 
washed with saturated brine (100 mL), dried (Na2S04), and the solvent removed Flash 
chromatography on silica with CH2C12:EtOAc (7:3) afforded 9.58 g (90%) of 2: mp 109-llO°C 
(Et0Ac:hexanes; 1:3): 1R (KBr) 3320, 1688 cm- l :  l H  NMR (CDC13) 6 7.43-6.87 (m, 14, Ar- 
H), 5.12 (s,  2, OC&Ar), 5.04 (s,  2, O C b A r ) ,  4.96 (d, 1, J=7.88 Hz, CHOH), 4.87 (s, 1, NH), 
4.07-4.02 (m, 1, CHCH3), 2.74 (s, 1, OH), 0.98 (d, 3, J=6.91 Hz, C b ) .  
Anal. Calcd. for C24H25N04: C, 73.63; H, 6.44; N, 3.58. Found: C, 73.68; 
H, 6.49; N, 3.47. 
( 1  R . 2 S ) - 3 - B e n z v l o x v - u - I I  - IN-methvlamino)ethvllbenzenemethanol (3 )  
A vigorously stirred mixture of lithium aluminum hydride (2.29 g, 60.3 mmol) in dry THF 
(60 mL) at OOC under argon was treated dropwise with a solution of 2 (3.94 g, 10.1 mmol) in dry 
THF (60 mL) over a period of 30 min. The reaction was warmed to room temperature and then 
refluxed for 6 h. The reaction mixture was cooled to O°C and treated cautiously with 60 ml of 
saturated (NH4)2S04, filtered, and the solid residue washed with hot EtOAc (100 mL). The filtrate 
was poured into saturated brine (100 mL) extracted with EtOAc (3 x 100 mL) and dried (NazS04). 
Removal of volatiles gave a pale yellow oil which was flash chromatographed on silica with 
CHC13:CH30H:NH40H (8:2:1) to afford 2.28 g (84%) of a clear oil that gave white crystals on 
standing. A small portion of this material was converted to the hydrochloride salt by treatment of an 
Et20 solution with dry HCI gas to give white fluffy crystals mp 166-167OC (EtOH:Et20 1:l) ;  H 
NMR (CDC13): 6 7.45-6.86 (m, 9, Ar-H), 5.07 (s, 2, O C b A r ) ,  4.75 (d, 1, J=3.80 Hz, CHOH), 
2.82-2.76 (m. 1, CHCHs), 2.47 (s, 3, NC&j), 0.83 (d, 3, J=6.51 Hz. C H C U ) .  
HRMS m/e 272.1641 (C1 7 H 2 2 N 0 2  (MH+) requires 272.1650). Anal. Calcd. for 
Ci7HzzCIN02 (HCI salt): C, 66.33; H, 7.20; N, 4.55. Found: C, 66.27; H, 7.08; N, 4.36. 
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( 1 R . S S )  - - -  I ) 3 - Hvdroxv - -  a [ I  - (N - m e - e t h v l l e n e w a n o l  (4)  
Five percent PdlC (200 mg) was added to a solution of 3 (2.12 g, 7.8 mmol) in CH30H (50 
mL) and hydrogenated at 50 psi for 6 h. The catalyst was removed by filtration through Celite and 
Solvent was removed under reduced pressure to afford a pale yellow oil which upon trituration with 
Et20 gave 1.359 (95%) of tan solid which was homogeneous by TLC. This was converted to the 
hydrochloride salt by passing HCI gas through an ethanol solution of the above; mp 218-22OoC 
(EtOH:Et20,1 : l) ;  [ c ~ ] D ~ ~ - ~ ~ . O ( C  5, C H ~ O H ) ; [ ~ ] D ~ ~ - ~ ~ . O ( C  5,CH30H) for authentic sample 
from Sterling Winthrop ( IR (KBr) 3470, 3160, 2970, 2760, c m - l .  H NMR 
(CD30D:CDCI3;1:1) 6 6.62 (t, 1, Ar-H), 6.26-6.13 (m, 3, Ar--H), 4.46 (d, 1 ,  J=3.02 Hz, 
CHOH), 4.16 (s, 3, NH, OH), 2.76-2.70 (m, 1, CYCH3), 2.15 (s, 1, N C b ) .  0.50 (d, 3, CHC&). 
Anal Calcd. for C10H16CIN02 (HCI salt): C, 55.17; H, 7.41; N, 6.43. Found: C. 55.17; H, 
7.44; N, 6.39. 
(1 R . 2 S ~ - 3 - H v d r o x v - 4 - i o d o - a - l l - ~ N - m e i h v l a m i n o ~ e i h v l l b e n z e n e m e i h a n o l  ( 5 ) .  
A solution of 4 (0.759, 4.1 mmol) in aqueous 10M NH40H (143 mL) was treated dropwise 
at room temperature under an argon atmosphere with a solution of 12 (1.09g, 4.3 mmol) in 95% 
EtOH (72 mL). The reaction mixture was stirred in the dark for 18h and concentrated under 
reduced pressure to give 2.369 of crystalline solid, which was treated with saturated brine (10 
mL) and extracted with EtOAc (3x50 mL). The combined organic layers were washed with aqueous 
10% Na2S203 (10 mL), dried (NazSOb), and evaporated to give 0.91g of pale yellow oil. Flash 
chromatography on silica with CHC13:CH30H:NH40H (7:3:0.1) provided 240 mg of cream colored 
crystals which were washed with ice-cold EtOAc (3 mL) followed by ice-cold CH3CN (3 mL) to 
afford 156 mg (12%) of white crystals homogeneous by TLC (silica; CHC13:CH30H:NH40H; 7:3:0.1; 
Rf=0.47; Rf of 4 = 0.10). Reverse phase HPLC analysis [Beckman Ultrasphere ODS, 4.6 x 150 
mm, 5-pm particle size, C-18 CH3CN: 0.2 M HCOONHq; (1:3) 1 mL min-l ]  retention time of 5. = 
9.7 min, retention time of 4 = 4.7 min; mp 206-208°C (d); H NMR (CD3COCD3) 6 7.64 (d, 1, 
J=8.52 Hz, Ar-H) 7.21 (d, 1, J=2.93 Hz, Ar-H), 6.70 (dd, 1, J1=3.02 Hz, Jp8.52  Hz, Ar-H), 
5.51 (brs, 1, NH or OH), 5.43 (d, 1, J=1.91 Hz, CHOH); 3.77-3.71 (m, 1, CHCHg) 3.02 (s, 3, 
N H C U ) ,  2.94 (br s, 2, NH, OH), 1.26 (d, 3, J=6.77 Hz, C H C U ) .  HRMS m/e 308.0146 
(C10H151N02 requires 308.0147) ClMS (isobutane), m/e (relative intensity) 308 (MH+. base), 
290 (35), 254 (12), 182 (43), 164 (20). 142 (16). 123 (15). 91 (7). 81 (9). 
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[ l R ) - 3 - H v d r o x v  _ _  4 i o d o  - -  a i l N  met(no l7L 
A rapidly stirred suspension of phenylephrine hydrochloride 6 (2.09, 9.8 mmol) in aqueous 
10M NH40H (340 mL) was treated dropwise with a solution of 12 (2.599, 10.2 mmol) in 95% 
EtOH (170 mL) under argon. Upon completion of the addition, the clear pale yellow solution was 
stirred at room temperature for 18 h. The reaction mixture was concentrated under reduced 
pressure and the resulting crystalline solid was dissolved in aqueous 5% NaHC03 (100 mL). 
Following filtration to remove a little solid residue, the clear aqueous solution gave fine white 
needles on standing overnight at 5OC. Recrystallization from CH30H afforded 0.86g (30%), mp 
164-166OC (d). ' H  NMR (DMSO-d6): d 7.55 (d, 1, J=8.03 Hz, Ar-H); 6.89 (d, 1, J=1.81 Hz, 
Ar-H); 6.54 (dd, 1, J1=1.81 Hz, J2d.06 Hz, Ar-H); 4.51 (t, 1, J 4 . 9  Hz, CHOH); 2.53 (d, 2, 
J=6.79 Hz, C&J; 2.28 (S, 3, N H C U ) .  
Anal. Calcd. for CgHi21N02: G 36.88; H 4,13; & 4.78. Found: C. 36.93; H 4.18; N 4.67. 
11 R . 2 S ) - ( - ) - 3 - H v d r o x v - 4 - L 3 ~ l - ~ - r 1 . ( N - m e t  h v l a r n i  n o ) e t  h v l l  b e n z e n e -  
methanol. 
[3H] 4 was prepared by the Amersham Corporation, Arlington Heights, IL., by catalytic 
deiodination as follows: To 5 (17 mg) dissolved in 0.2 M sodium phosphate (2 mL, pH 7) was added 
10% Pd on charcoal (10 mg) and 10% Pd on CaC03 (10 mg) and the mixture stirred with tritium 
gas (10 Ci) at atmospheric pressure and room temperature for 16h (when uptake of tritium had 
ceased). The reaction mixture was filtered through a Millipore-HA filter and the filtsr washed with 
H 2 0  (10 mL) followed by EtOH (10 mL). Following removal of the labile tritium by repeated 
evaporation with EtOH (3x5 mL); the residue was formulated in EtOH (25 mL) to give 170 mCi of 
[3H] 4. The radiochemical purity was 88% as assessed by the following TLC systems. 
1) Silica; CHC13:CH30H:NH40H (7:3:0.1) Rf of 4 = 0.14 Rf of 5 = 0.35. 
2) C-18; CH3CN: 0.2 M HCOO-NH'4 (1 :1) Rf of 4 = 0.50. 
The labeled product was stored at -2OOC in EtOH at a concentration of 1 mCi/mL. Further 
purification of a portion of this material was achieved by reverse phase preparative HPLC as 
follows: A 10 mL EtOH solution of the above (10 mCi) was concentrated under reduced pressure at 
3OoC to a volume of approximately 0.5 mL and then diluted with 10 mM acetic acid (1 mL). 
Residual EtOH was removed by further evaporation under reduced pressure and the crude mixture 
(approximately 1 mL) purified by preparative HPLC [Beckman Ultrasphere ODs, 4.6 x 250 m m  
with guard column, 5-pm particle size, C-18 0.2 M HOAc in 95% EtOH:H20 (1:9) 1 mL min-l, 
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with radioactivity detection (Flo-one)] to afford 8.5 mCi of product in 98% radiochemical and 
chemical purity. The retention times for L3H] L a n d  5 was 7.3 min and 36.3 min respectively 
under these conditions and the specific activity of the purified product was 22 Ci mmol-l . 
1 R ) - I - )  -3- H v d r ox  v -4-[3 H 1 -a  - II N - m e t  h v I a m i n o 1 m e t  h v I1 b e  n n e m e t h a n o l .  
A procedure analogous to that described for the synthesis of [3H] 4 utilizing 15 mg of I 
provided 670 mCi of [3H] 6. The radiochemical purity was 99% as assessed by the following TLC 
systems. 
1) Silica; n-BuOH:HOAc:H20 (435) Rf of 5 = 0.40 
2) C-18; THF: 0.2 M NH4H2P04 (3~7) Rf Of 6 = 0.60. 
Further purification was conducted by reversg phase HPLC (same system as described for that of 
[3H] 4) to ensure that the product was chemically pure. The retention times for [3H] 6 and were 
6.70 and 30 min, respectively, and the specific activity of the product was 29 Ci mmol-l. 
Acid cata lvzed isomer izat ion o f I l R . 2 9  - - -  I 1 meta - h v d r o x v e D h e a  
A solution of 4 (8.0 mg, 0.037 mmoies) in 6N HCI (2 mL) was refluxed with stirring for 
48 h. The reaction mixture was evaporated to dryness and the residue dried under high 
vacuum at 80OC. Analysis by 1H NMR (CDCl3:CD3OD; 1:l by volume with TMS as internal 
standard) showed the relative concentration of the erythro and threo isomers to be 7:3 by 
integration of the erythro-and threo-H, doublets, respectively. The erythro-H, doublet (1 R, 2s 
configuration) was centered at 4.43 ppm. J=2.74 Hz and the threo-H1 doublet (IS, 2s  
configuration) was centered at 3.84 ppm, J=9.06 Hz. The racemized mixture was also analysed by 
HPLC (Waters Associates p Bondapak, 3.9 x 300 mm, 5-pn particle size, C-18; 0.2 M 
NH4H2P04; 1 mL min-1). Retention times for the erythro and threo isomers were 11.24 and 
15.52 min, respectively. 
Confirmation of retention of oDtical activitv du  rina cata lvtic hvdroaenat ion. 
Catalytic hydrogenation of 3 conducted as described for the synthesis of r3H] egave m- 
hydroxyephedrine 4JaIDz5 -34.6 (C 5, CH30H); ([aIDz5 -35.2 (C 5, CH30H) for the authentic 
free base form of 4.). Similarly hydrogenation of L gave phenylephrine fi [aIDz5-32.6 (c 5,  
CH30H); {[a]D25-31.6 (C 5, CH30H) ior the authentic free base form of a. 
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